What is Genscript Biotech Price-to-Operating-Cash-Flow?
As of today (2024-06-03), Genscript Biotech's share price is HK$8.23.
Genscript Biotech's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-1.07. Hence, Genscript Biotech's Price-to-Operating-Cash-Flow Ratio for today is .
The historical rank and industry rank for Genscript Biotech's Price-to-Operating-Cash-Flow or its related term are showing as below:
During the past 10 years, Genscript Biotech's highest Price-to-Operating-Cash-Flow Ratio was 318.04. The lowest was 8.18. And the median was 23.38.
Genscript Biotech's Cash Flow from Operations per share for the
six
months ended in Dec. 2023 was HK$-0.37.
Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-1.07.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -19.90% per year.
During the past 10 years, Genscript Biotech's highest 3-Year average Operating Cash Flow per Share Growth Rate was 119.30% per year. The lowest was -52.50% per year. And the median was -0.95% per year.
Genscript Biotech Price-to-Operating-Cash-Flow Historical Data
The historical data trend for Genscript Biotech's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genscript Biotech Price-to-Operating-Cash-Flow Chart
|
Genscript Biotech Annual Data
|
|
Trend |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Price-to-Operating-Cash-Flow |
|
Get a 7-Day Free Trial
|
|
|
- |
- |
- |
- |
- |
|
Genscript Biotech Semi-Annual Data
|
|
Dec14 |
Jun15 |
Dec15 |
Jun16 |
Dec16 |
Jun17 |
Dec17 |
Jun18 |
Dec18 |
Jun19 |
Dec19 |
Jun20 |
Dec20 |
Jun21 |
Dec21 |
Jun22 |
Dec22 |
Jun23 |
Dec23 |
| Price-to-Operating-Cash-Flow |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
- |
- |
- |
- |
- |
Competitive Comparison of Genscript Biotech's Price-to-Operating-Cash-Flow
For the Biotechnology subindustry, Genscript Biotech's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genscript Biotech's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genscript Biotech's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Genscript Biotech's Price-to-Operating-Cash-Flow falls into.
Genscript Biotech Price-to-Operating-Cash-Flow Calculation
Genscript Biotech's Price-to-Operating-Cash-Flow ratio for today is calculated as
| Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
| = | 8.23 | / | -1.065 |
| = | |
Genscript Biotech's Share Price of today is HK$8.23.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Genscript Biotech's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-1.07.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
Genscript Biotech (HKSE:01548) Business Description
Traded in Other Exchanges
Address
No. 28, Yongxi Road, Jiangning Science Park, Jiangsu Province, Nanjing, CHN, 211100
GenScript Biotech is a China-based provider of life science research services and products. Founded in 2002, it is best known for its gene synthesis capabilities, a widely used service by academics, biotech companies, and pharmaceutical companies around the world. Its business lines include life science research services and products, biologics development services under its ProBio brand, and industrial enzymes under its Bestzyme brand. Finally, it owns 57.1% of Nasdaq-listed Legend Biotech, whose key pipeline asset is a BCMA-targeting CAR-T treatment for multiple myeloma. We estimate that more than two thirds of GenScript's valuation is from its ownership stake in Legend.
Executives
Genscript Biotech (HKSE:01548) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:01548 has been successfully added to your